A One-year Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients With Moderately to Severely Active Crohn's Disease (CD) in China
Latest Information Update: 03 Feb 2025
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Sponsors AbbVie
Most Recent Events
- 29 Jan 2025 Status changed from active, no longer recruiting to completed.
- 19 Jun 2024 Planned End Date changed from 21 Jul 2024 to 28 Feb 2025.
- 19 Jun 2024 Planned primary completion date changed from 21 Jul 2024 to 28 Feb 2025.